U.S. Food Stock News

Cousins Properties (CUZ) is drawing attention after recent price moves, with the stock closing at US$25.83 as investors weigh its role as a Sun Belt focused office REIT and assess its current valuation. See our latest analysis for Cousins Properties. The recent pullback, including a 2.57% 1 day share price decline, comes after a 6.56% 30 day share price return. The 1 year total shareholder return of an 8.69% decline contrasts with a 17.94% gain over three years, suggesting longer term...

Recent attention on Napco Security Technologies (NSSC) centers on its 10.2% annual revenue growth and 12.8% annual net income growth, along with solid free cash flow and higher returns on capital that highlight management’s capital allocation. See our latest analysis for Napco Security Technologies. Even with recent choppy trading, including a 4.2% decline in the 90 day share price return and a 1 year total shareholder return of 19%, momentum still looks more supportive over the longer term...

In recent days, Teladoc Health has continued to face pressure as competition intensifies, BetterHelp loses paying members, and the company remains unprofitable despite cost-control efforts and AI investments. This combination of weakening growth in a core mental health business, rising rivalry from large tech and insurance players, and cautious analyst sentiment has reinforced investor concerns about Teladoc’s longer-term business trajectory. We’ll now examine how BetterHelp’s member losses...

Zymeworks Inc. recently reported positive Phase 3 HERIZON-GEA-01 results showing that Ziihera (zanidatamab-hrii) plus chemotherapy, with or without Tevimbra (tislelizumab), improved progression-free and overall survival versus trastuzumab plus chemotherapy in adults with HER2-positive metastatic gastroesophageal adenocarcinoma, with data presented as a late-breaking oral session at the 2026 ASCO-GI symposium. The trial’s efficacy and manageable safety profile could support Ziihera’s use as a...

Why CarGurus (CARG) is on investors’ radar today CarGurus (CARG) is drawing attention after recent share price moves, with the stock closing at US$37.97 and posting mixed short term returns alongside stronger gains over the past 3 months and year. See our latest analysis for CarGurus. While the 1 day and 7 day share price returns have been slightly negative, the 30 day and 90 day share price returns of 7.23% and 11.71% suggest momentum has been building, alongside a 3 year total shareholder...

Arrowhead Pharmaceuticals (ARWR) is in focus after early clinical data for its obesity candidates ARO-INHBE and ARO-ALK7, along with new approvals for REDEMPLO in Canada and China, highlighted progress across its RNAi pipeline. See our latest analysis for Arrowhead Pharmaceuticals. Despite the positive obesity data and fresh REDEMPLO approvals, Arrowhead’s 1-day share price return of a 7.23% decline and 30-day share price return of a 4.24% decline contrast with a sharp 90-day share price...

Aflac recently disclosed that a sophisticated cyberattack affected about 22.65 million individuals and has since partnered with CyEx to provide its Medical Shield medical fraud protection service, offering monitoring that extends beyond standard credit checks. This move underscores how cybersecurity and post-breach care are becoming core parts of the value proposition for major supplemental health and life insurers like Aflac. Now we’ll explore how Aflac’s cyber incident response, including...

BridgeBio Pharma recently announced an investor webinar held on January 9, 2026, to discuss achondroplasia and Phase 3 PROPEL 3 data for infigratinib, alongside upcoming presentations at the J.P. Morgan Healthcare Conference. This focus on late-stage clinical progress comes as analysts highlight BridgeBio’s growing commercial footprint with Attruby and its broader rare disease pipeline, while investors scrutinize insider selling activity. We’ll now examine how the insider selling and...

Why Sionna Therapeutics (SION) is on investors’ radar today Sionna Therapeutics (SION) has attracted fresh attention after a recent 16.1% one day move, as investors reassess this clinical stage cystic fibrosis developer. See our latest analysis for Sionna Therapeutics. That 16.1% one day share price return comes on top of a 46.9% 90 day share price return and a 10.2% year to date gain, suggesting momentum has been building rather than fading, with the stock now at $43.21. If you are looking...

Genesis Energy (NYSE:GEL) has drawn attention after its recent trading performance, with a 5% decline over the past month and a 1% slip over the past three months prompting closer scrutiny of its fundamentals. See our latest analysis for Genesis Energy. While the recent 1-month share price return of 4.75% and 3-month share price return of 1.04% are both negative, Genesis Energy’s 1-year total shareholder return of 54.33% and 5-year total shareholder return of about 3x suggest longer term...

Aurora Innovation recently expanded its autonomous trucking footprint through partnerships involving Amazon Web Services, German supplier Aumovio, Nvidia, Continental, and logistics firm Detmar, building on its status as the first company to commercially operate driverless heavy-duty trucks on U.S. public roads. A particularly interesting angle is Aurora’s move into autonomous frac sand hauling in the Permian Basin, which shows how its driverless technology is being customized for complex,...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

If you are wondering whether Vertiv Holdings Co at US$171.54 is still priced reasonably or already stretched, you are not alone. The stock has been volatile recently, with a 5.9% gain over the last 7 days, a 7.6% decline over 30 days, a 2.3% decline year to date, and a 32.9% return over the past year, while its 3 year and 5 year returns are described as very large. These swings have kept Vertiv on many investors' watchlists, as rapid multi year moves often prompt questions about what is...

UBS recently initiated research coverage on Oruka Therapeutics with a positive rating and a US$50 price target, spotlighting the clinical‑stage biotech’s peptide‑based oncology and immune‑mediated disease programs. This coverage effectively elevates Oruka’s profile among institutional investors by framing its pipeline as part of a broader recovery narrative in the biotech sector. Next, we’ll examine how UBS’s new coverage and its emphasis on Oruka’s peptide‑based oncology platform shape the...

The Council of Fashion Designers of America and Ralph Lauren Corporation recently launched two grant programs to support modernizing, expanding, and training within New York City’s Garment District and apparel manufacturers across the U.S. By backing these manufacturing funds, Ralph Lauren is reinforcing its role in shaping the American fashion supply chain and production capabilities alongside its premium brand focus. We’ll now examine how Ralph Lauren’s support for U.S. fashion...

LandBridge (LB) is in focus after agreeing to acquire 1918 Ranch. The deal is expected to add about $20 million in EBITDA for fiscal 2026, alongside fresh debt and equity financing moves. See our latest analysis for LandBridge. Those moves come after a tough stretch for the stock, with a 30-day share price return decline of 23.24% and a 1-year total shareholder return decline of 38.19%, suggesting momentum has been fading despite recent capital raising and acquisition news. If this kind of...

ZipRecruiter, Inc.'s (NYSE:ZIP) stock price has dropped 10.0% in the previous week, but insiders who sold US$887k in...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

A Montana federal judge has allowed a high profile class-action lawsuit over toxic PFAS chemicals in firefighter gear to proceed against Chemours (CC) and other manufacturers, keeping potential liability and reputational questions in focus for shareholders. See our latest analysis for Chemours. Chemours shares trade at US$13.07, with a 7 day share price return of 10.86% and a 30 day gain of 7.13%. However, a 1 year total shareholder return decline of 24.19% and a 3 year total shareholder...

In the fourth quarter of 2025, Texas-based Kopion Asset Management increased its holdings in Tennant to 123,037 shares, investing about US$9.07 million as the company expanded profitability and generated strong free cash flow despite a volume downturn. Tennant’s ability to lift its dividend, repurchase US$28 million of stock, and keep net leverage below one times adjusted EBITDA signals management’s confidence in the resilience of its industrial cleaning business model. We’ll now examine how...

If you are wondering whether NVIDIA's share price still makes sense after its large rise, the key question is how that price compares with what the business might be worth. NVIDIA closed at US$189.11, with returns of 1.4% over the last 7 days, 2.2% over the last 30 days, 0.1% year to date, 35.0% over 1 year and a very large gain over 3 and 5 years. Recent market attention has centered on NVIDIA's role in graphics processing units and data center chips used in areas like gaming, artificial...

Recent gains in Applied Materials (AMAT) have been closely tied to strong interest in artificial intelligence related chip spending, as investors focus on data center growth, memory and logic demand, and upcoming earnings guidance. See our latest analysis for Applied Materials. The latest rally has come after a series of strong daily moves tied to AI themed chip equipment enthusiasm and expectations for the 12 February earnings update, with a 90 day share price return of 32.64% and a 1 year...

Nutanix (NTNX) is drawing fresh attention after partnering with Abu Dhabi based Saal.ai to launch SovereignGPT, an AI platform designed for security focused firms that want data to remain within their own infrastructure. See our latest analysis for Nutanix. The SovereignGPT announcement comes after a softer quarter that coincided with a roughly 34% share price decline over the past six months. Nutanix now trades at US$53.26 with a 30 day share price return of 12.39%, while the three year...

If you are wondering whether Sandisk's share price still offers value or if the recent run has gone too far, this article will walk through what the numbers are saying today. Sandisk last closed at US$353.56, with returns of 48.9% over 7 days, 61.1% over 30 days and 28.5% year to date, which has naturally raised questions about future risk and reward. Recent headlines around Sandisk have focused on its position in the broader tech sector and how sentiment toward the stock has shifted as...